Expression And Clinical Significance Of G6PD And PKM2 In Lung Adenocarcinoma

Research BackgroundLung cancer is the most common cancer in China and its death rate ranks first among various malignant tumors.According to the statistics of the 2012 China Cancer Registry Annual Report,the incidence of lung cancer in China is 54.75 per 100,000,and the mortality rate is 46.07 per 100,000,ranking first among all types of malignant tumors,and lung adenocarcinoma has become the most common form of lung adenocarcinoma.Most patients are locally advanced at the time of initial diagnosis,have a relatively high recurrence rate,and have a relatively low 5-year survival rate.With the continuous development of targeted therapy and immunotherapy,this has given new hope to patients with advanced lung cancer,but not many patients have benefited,and drug resistance problems will inevitably occur.It is necessary to conduct a more in-depth study on the mechanism of occurrence and development of lung cancer.Many reports suggest that glucose-6-phosphate dehydrogenase(G6PD)and pyruvate kinase M2(PKM2)play an extremely important role in the development of cancer,but the mechanism of G6PD and PKM2 for the occurrence and development of lung adenocarcinoma cancer is still unknown.ObjectiveIn this study,we examined the expression of G6PD and PKM2 in lung adenocarcinoma cancer tissues to explore how they are related to clinicopathological features,and analyze the correlation between the two in lung adenocarcinoma cancer tissues.Preliminary exploration and discussion of the expression and significance of G6PD and PKM2 in lung cancer provide important support for further research on the role of G6PD and PKM2 in the development of lung adenocarcinoma cancer.,finally analyze the correlation between G6PD and PKM2.MethodIn this experiment,we mainly used immunohistochemistry to detect the expression of G6PD protein and PKM2 protein in the cancer tissues of 49 patients with lung adenocarcinoma.The 49 patients were all from the cancer tissues of lung adenocarcinoma patients who underwent surgical treatment from September 2012 to July 2017 in our hospital.The relationship between the expression of G6PD and PKM2 in them and the characteristics of clinical cases was analyzed.Combined with clinical data such as the age of onset and clinical stage of 49 patients,statistical methods were used to compare and analyze the relationship between G6PD protein and PKM2 protein expression levels and clinical parameters.Result1.The relationship between G6PD and clinicopathological characteristics of patients with lung adenocarcinoma: In 49 patients,the high expression of G6PD is closely related to the lymph nodes The G6PD expression level of patients with metastasis was higher than that of patients without lymph node metastasis,and the difference was statistically significant(χ~2 = 4.864,P = 0.027).2.The relationship between PKM2 and clinicopathological characteristics of patients with lung adenocarcinoma: In 49 patients,the high expression of PKM2 is closely related to the lymph nodes The G6PD expression level of metastatic patients was higher than that of patients without lymph node metastasis,and the difference was statistically significant(χ~2= 4.128,P = 0.042).3.Spearman correlation analysis showed that G6PD expression was positively correlated with PKM2 expression,and the correlation was significant(R = 0.534,P <0.0001).Conclusion1.The expression levels of G6PD and PKM2 protein molecules are related to lymph node metastasis of lung adenocarcinoma,which suggests that G6PD and PKM2 may become the reference indicators for clinical staging of patients with lung adenocarcinoma.2.The expression levels of G6PD and PKM2 protein molecules have nothing to do with age,gender,smoking history.3.The expression of G6PD and PKM2 showed a linear positive correlation.